Most Americans And Canadians With HIV Diagnosed Too Late

Most Americans And Canadians With HIV Diagnosed Too Late.
Americans and Canadians infected with HIV are not getting diagnosed without delay enough after exposure, resulting in a potentially toxic set back in lifesaving treatment, a new large study suggests. The observation stems from an inquiry involving nearly 45000 HIV-positive patients in both countries, which focused on a key yardstick for untouched system strength - CD4 cell counts - at the time each patient beginning began treatment. CD4 counts measure the number of "helper" T-cells that are HIV's preferred target.

Reviewing the participants' medical records between 1997 and 2007, the pair found that throughout the 10-year study period, the run-of-the-mill CD4 count at the time of first treatment was below the recommended level that scientists have elongate identified as the ideal starting point for medical care. "The public health implications of our findings are clear," turn over author Dr Richard Moore, from the Johns Hopkins University School of Medicine in Baltimore, said in a message release. "Delayed diagnosis reduces survival, and individuals enter into HIV supervision with lower CD4 counts than the guidelines for initiating antiretroviral therapy". A dilly-dallying in getting treatment not only increases the chance that the disease will progress, but boosts the risk of transmission.

Despite the episode that the average CD4 count at time of first presentation to care had risen over the orbit of the decade from 256 to 317, the researchers noted that even the high point was still below the treatment threshold of 350. Moore and his troupe also found that the average age at which patients had first sought care for HIV had risen over the ten-year period, from 40 to 43.

Writing in an opinion piece that accompanied the study, Dr Cynthia Gay of the University of North Carolina at Chapel Hill expressed reference to over the findings. "These findings disclose that despite such compelling data, there is much room for improving our ability to link more HIV-infected individuals with basic treatment prior to immunological deterioration," she said in a news release where to find vigrx oil in new hampshire. Moore and his colleagues dispatch their findings in the June 1 issue of Clinical Infectious Diseases.